Andrew Tsai
Stock Analyst at Jefferies
(3.32)
# 1,055
Out of 5,182 analysts
28
Total ratings
54.17%
Success rate
3.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $168.51 | +45.40% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $20.68 | +45.07% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.59 | +53.43% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $49.20 | -39.02% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $310.38 | +44.98% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $21.17 | +51.16% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $21.68 | +15.31% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $177.34 | +7.14% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $23.23 | +50.67% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $32.74 | -8.37% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $73.15 | -4.31% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.55 | -29.58% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $14.81 | +82.31% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $6.99 | +85.98% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $33.58 | +4.23% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.59 | +88.68% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.79 | +612.40% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $56.85 | -59.54% | 1 | Jun 1, 2020 |
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $168.51
Upside: +45.40%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $20.68
Upside: +45.07%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.59
Upside: +53.43%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $49.20
Upside: -39.02%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $310.38
Upside: +44.98%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $21.17
Upside: +51.16%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $21.68
Upside: +15.31%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $177.34
Upside: +7.14%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $23.23
Upside: +50.67%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $32.74
Upside: -8.37%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $73.15
Upside: -4.31%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.55
Upside: -29.58%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $14.81
Upside: +82.31%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $6.99
Upside: +85.98%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $33.58
Upside: +4.23%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.59
Upside: +88.68%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.79
Upside: +612.40%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $56.85
Upside: -59.54%